Skip to content

19-383 - A Study of Suboptimally Controlled Participants Previously Taking Oral Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS)

Status: open

Cladribine tablets: Observational evaluation of effectiveness and patient-reported outcomes (PROs) in suboptiMAlly controlled patientS previously Taking oral disEase-modifying dRugs (DMDs) for relapsing forms of multiple sclerosis (RMS) (MASTER-2)

Patients with relapsing Multiple Sclerosis (RMS)

Contact Us Or call +1 (251) 665-8375


The purpose of this study is to evaluate the effectiveness and safety of cladribine tablets in participants with relapsing form of multiple sclerosis (RMS) including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS) who transition to cladribine tablets after suboptimal response to any oral DMD approved in the United States for RMS in a real-world setting.


This trial is sponsored by Merck.

Providers Associated With This Trial

Sub Investigators

This link will open in a new tab or window.